vs
First Guaranty Bancshares, Inc.（FGBI）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是First Guaranty Bancshares, Inc.的1.4倍（$30.3M vs $22.3M），First Guaranty Bancshares, Inc.净利率更高（12.1% vs -221.3%，领先233.4%），REGENXBIO Inc.同比增速更快（43.0% vs -10.9%），First Guaranty Bancshares, Inc.自由现金流更多（$-10.0M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -4.0%）
第一公民银行股份公司是一家银行控股公司，总部位于北卡罗来纳州罗利，是美国规模最大的银行之一。公司主要子公司为第一公民银行，在全美23个州开设了超过500家分行；另一家子公司为硅谷银行，在15个州共设有39个办事处。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
FGBI vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.4倍
$22.3M
营收增速更快
RGNX
高出53.9%
-10.9%
净利率更高
FGBI
高出233.4%
-221.3%
自由现金流更多
FGBI
多$42.8M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-4.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $22.3M | $30.3M |
| 净利润 | $2.5M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 14.4% | -190.0% |
| 净利率 | 12.1% | -221.3% |
| 营收同比 | -10.9% | 43.0% |
| 净利润同比 | 142.6% | -31.2% |
| 每股收益（稀释后） | — | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FGBIRGNX
| Q4 25 | $22.3M | $30.3M | ||
| Q3 25 | $24.1M | $29.7M | ||
| Q2 25 | $24.4M | $21.4M | ||
| Q1 25 | $24.6M | $89.0M | ||
| Q4 24 | $25.1M | $21.2M | ||
| Q3 24 | $27.1M | $24.2M | ||
| Q2 24 | $36.8M | $22.3M | ||
| Q1 24 | $24.2M | $15.6M |
净利润FGBIRGNX
| Q4 25 | $2.5M | $-67.1M | ||
| Q3 25 | $-45.0M | $-61.9M | ||
| Q2 25 | $-7.3M | $-70.9M | ||
| Q1 25 | $-6.2M | $6.1M | ||
| Q4 24 | $1.0M | $-51.2M | ||
| Q3 24 | $1.9M | $-59.6M | ||
| Q2 24 | $7.2M | $-53.0M | ||
| Q1 24 | $2.3M | $-63.3M |
毛利率FGBIRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率FGBIRGNX
| Q4 25 | 14.4% | -190.0% | ||
| Q3 25 | -224.1% | -176.3% | ||
| Q2 25 | -38.9% | -296.3% | ||
| Q1 25 | -32.5% | 13.6% | ||
| Q4 24 | 4.7% | -242.1% | ||
| Q3 24 | 9.2% | -256.6% | ||
| Q2 24 | 25.4% | -251.3% | ||
| Q1 24 | 12.3% | -408.8% |
净利率FGBIRGNX
| Q4 25 | 12.1% | -221.3% | ||
| Q3 25 | -186.7% | -208.3% | ||
| Q2 25 | -29.9% | -331.8% | ||
| Q1 25 | -25.1% | 6.8% | ||
| Q4 24 | 4.0% | -241.3% | ||
| Q3 24 | 7.1% | -246.3% | ||
| Q2 24 | 19.6% | -237.7% | ||
| Q1 24 | 9.5% | -405.4% |
每股收益（稀释后）FGBIRGNX
| Q4 25 | — | $-1.30 | ||
| Q3 25 | — | $-1.20 | ||
| Q2 25 | — | $-1.38 | ||
| Q1 25 | — | $0.12 | ||
| Q4 24 | — | $-0.99 | ||
| Q3 24 | — | $-1.17 | ||
| Q2 24 | — | $-1.05 | ||
| Q1 24 | — | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | $179.0M | — |
| 股东权益账面价值 | $226.2M | $102.7M |
| 总资产 | $4.1B | $453.0M |
| 负债/权益比越低杠杆越低 | 0.79× | — |
8季度趋势，按日历期对齐
现金及短期投资FGBIRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
总债务FGBIRGNX
| Q4 25 | $179.0M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $194.9M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益FGBIRGNX
| Q4 25 | $226.2M | $102.7M | ||
| Q3 25 | $221.1M | $161.5M | ||
| Q2 25 | $263.1M | $213.7M | ||
| Q1 25 | $251.4M | $274.2M | ||
| Q4 24 | $255.0M | $259.7M | ||
| Q3 24 | $256.4M | $301.4M | ||
| Q2 24 | $255.1M | $348.3M | ||
| Q1 24 | $250.3M | $390.7M |
总资产FGBIRGNX
| Q4 25 | $4.1B | $453.0M | ||
| Q3 25 | $3.8B | $525.2M | ||
| Q2 25 | $4.0B | $581.0M | ||
| Q1 25 | $3.8B | $490.9M | ||
| Q4 24 | $4.0B | $466.0M | ||
| Q3 24 | $3.9B | $519.1M | ||
| Q2 24 | $3.6B | $569.4M | ||
| Q1 24 | $3.6B | $629.2M |
负债/权益比FGBIRGNX
| Q4 25 | 0.79× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.76× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-8.3M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-10.0M | $-52.8M |
| 自由现金流率自由现金流/营收 | -44.6% | -174.0% |
| 资本支出强度资本支出/营收 | 7.6% | 1.7% |
| 现金转化率经营现金流/净利润 | -3.38× | — |
| 过去12个月自由现金流最近4个季度 | $5.4M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流FGBIRGNX
| Q4 25 | $-8.3M | $-52.3M | ||
| Q3 25 | $29.4M | $-56.0M | ||
| Q2 25 | $-18.3M | $-49.3M | ||
| Q1 25 | $5.4M | $33.6M | ||
| Q4 24 | $33.7M | $-31.6M | ||
| Q3 24 | $4.9M | $-40.5M | ||
| Q2 24 | $7.9M | $-45.5M | ||
| Q1 24 | $2.0M | $-55.5M |
自由现金流FGBIRGNX
| Q4 25 | $-10.0M | $-52.8M | ||
| Q3 25 | $28.7M | $-56.5M | ||
| Q2 25 | $-18.6M | $-49.7M | ||
| Q1 25 | $5.2M | $32.6M | ||
| Q4 24 | $30.7M | $-32.7M | ||
| Q3 24 | $4.7M | $-40.9M | ||
| Q2 24 | $6.6M | $-46.0M | ||
| Q1 24 | $396.0K | $-56.0M |
自由现金流率FGBIRGNX
| Q4 25 | -44.6% | -174.0% | ||
| Q3 25 | 119.3% | -189.9% | ||
| Q2 25 | -76.2% | -232.8% | ||
| Q1 25 | 21.1% | 36.6% | ||
| Q4 24 | 122.4% | -154.2% | ||
| Q3 24 | 17.4% | -168.9% | ||
| Q2 24 | 18.0% | -206.2% | ||
| Q1 24 | 1.6% | -358.5% |
资本支出强度FGBIRGNX
| Q4 25 | 7.6% | 1.7% | ||
| Q3 25 | 2.9% | 1.7% | ||
| Q2 25 | 1.1% | 1.8% | ||
| Q1 25 | 0.8% | 1.2% | ||
| Q4 24 | 12.1% | 5.1% | ||
| Q3 24 | 0.5% | 1.3% | ||
| Q2 24 | 3.5% | 2.1% | ||
| Q1 24 | 6.6% | 3.6% |
现金转化率FGBIRGNX
| Q4 25 | -3.38× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | 33.40× | — | ||
| Q3 24 | 2.52× | — | ||
| Q2 24 | 1.10× | — | ||
| Q1 24 | 0.86× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FGBI
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
